NASDAQ · Financial Statements

Collegium Pharmaceutical, Inc. (COLL) Financial Statements

$22.96 NASDAQ: COLL Market Cap $747.48M

Collegium Pharmaceutical, Inc. most recently reported annual revenue of $781.0M, net profit of $63.0M. Revenue grew at an average annual rate of 20.3% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Collegium Pharmaceutical, Inc.: Revenue rose from $2.0M in 2016 to $781.0M in 2025, a change of +38950.0% over 9 years; net profit was positive in 5 of 10 reported years; operating margin moved from -5498.7% to 24.0%, a shift of +5522.6 percentage points; the most recent year shows net profit of $63.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$2.0M$28.0M$280.0M$297.0M$310.0M$277.0M$464.0M$567.0M$631.0M$781.0M
Operating Expenses$96.0M$104.0M$301.0M$320.0M$254.0M$259.0M$431.0M$400.0M$462.0M$593.0M
Operating Profit$-94.0M$-75.0M$-21.0M$-24.0M$56.0M$18.0M$33.0M$167.0M$170.0M$187.0M
Operating Margin-5498.7%-264.9%-7.4%-8.0%18.1%6.4%7.2%29.5%26.9%24.0%
Other Income$0$1.0M$-18.0M$1.0M$-29.0M$-21.0M$-62.0M$-91.0M$-71.0M$-94.0M
Interest$0$0$20.0M$1.0M$29.0M$21.0M$63.0M$83.0M$74.0M$82.0M
Depreciation$1.0M$1.0M$111.0M$15.0M$62.0M$69.0M$139.0M$149.0M$169.0M$226.0M
Profit Before Tax$-94.0M$-75.0M$-39.0M$-23.0M$28.0M$-3.0M$-29.0M$76.0M$99.0M$93.0M
Tax$-100,000$0$0$0$3.0M$2.2B$13.3M$36.4M$29.8M$32.1M
Net Profit$-94.0M$-75.0M$-39.0M$-23.0M$27.0M$72.0M$-25.0M$48.0M$69.0M$63.0M
EPS$-3.88$-2.47$-1.19$-0.24$0.76$1.86$-0.74$1.29$1.86$1.73
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$137.0M$150.0M$145.0M$145.0M$159.0M$182.0M$178.0M$188.0M$209.0M$205.0M$194.0M$200.0M
Operating Expenses$92.0M$88.0M$95.0M$98.0M$124.0M$144.0M$156.0M$153.0M$146.0M$146.0M$162.0M$196.0M
Operating Profit$45.0M$62.0M$49.0M$47.0M$35.0M$38.0M$22.0M$35.0M$64.0M$59.0M$32.0M$4.0M
Operating Margin32.9%41.2%34.1%32.7%21.9%20.9%12.2%18.7%30.4%28.8%16.5%1.9%
Interest$21.0M$19.0M$17.0M$16.0M$18.0M$23.0M$21.0M$20.0M$22.0M$105.0M$16.0M$20.0M
Profit Before Tax$29.0M$47.0M$37.0M$29.0M$16.0M$17.0M$3.0M$17.0M$43.0M$29.0M$19.0M$-14.0M
Tax$28.3M$31.6M$24.3M$32.6M$40.1M$27.4M$22.6M$29.6M$27.5M$41.6M$22.6M$-11.2M
Net Profit$21.0M$32.0M$28.0M$20.0M$9.0M$13.0M$2.0M$12.0M$32.0M$17.0M$14.0M$-15.0M
EPS$0.53$0.82$0.71$0.52$0.27$0.35$0.07$0.34$0.84$0.46$0.40$-0.46

Over the 10 years reported for Collegium Pharmaceutical, Inc., borrowings increased from $4.0M in 2016 to $941.0M in 2025, cash stood at $251.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 1.57 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$162.0M$136.0M$291.0M$306.0M$644.0M$692.0M$1.2B$1.1B$1.7B$1.7B
Current Assets$159.0M$133.0M$238.0M$256.0M$278.0M$316.0M$420.0M$538.0M$482.0M$691.0M
Cash$153.0M$119.0M$147.0M$170.0M$174.0M$186.0M$174.0M$239.0M$71.0M$251.0M
Inventory$1.0M$2.0M$8.0M$10.0M$16.0M$17.0M$47.0M$32.0M$36.0M$41.0M
Receivables$2.0M$10.0M$78.0M$73.0M$83.0M$106.0M$183.0M$180.0M$229.0M$211.0M
Fixed Assets$1.0M$2.0M$9.0M$21.0M$27.0M$27.0M$26.0M$22.0M$20.0M$16.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$3.0M$3.0M$72.0M$92.0M$156.0M
Other Assets$0$0$0$0$0$0$134.0M$134.0M$162.0M$146.0M
Total Liabilities$27.0M$31.0M$200.0M$219.0M$458.0M$489.0M$979.0M$948.0M$1.4B$1.4B
Current Liabilities$23.0M$31.0M$187.0M$202.0M$239.0M$280.0M$434.0M$458.0M$510.0M$440.0M
Borrowings$4.0M$1.0M$12.0M$22.0M$267.0M$259.0M$709.0M$674.0M$859.0M$941.0M
Other Liabilities$23.0M$30.0M$188.0M$197.0M$191.0M$230.0M$270.0M$274.0M$575.0M$415.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$135.0M$104.0M$92.0M$87.0M$186.0M$203.0M$195.0M$195.0M$229.0M$302.0M

For Collegium Pharmaceutical, Inc., operating cash flow was positive in 8 of 10 reported years; free cash flow in the latest year was $328.0M; free cash flow was positive in 7 of 10 years; financing activities used $46.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$-75.0M$-67.0M$169.0M$28.0M$94.0M$104.0M$124.0M$275.0M$205.0M$329.0M
Investing Cash Flow$-8.0M$-2.0M$-68.0M$-13.0M$-748.0M$-4.0M$-575.0M$-71.0M$-289.0M$-65.0M
Financing Cash Flow$1.0M$2.0M$-128.0M$2.0M$5.0M$-39.0M$-6.0M$-74.0M$-68.0M$-46.0M
Net Cash Flow$58.0M$-35.0M$28.0M$23.0M$7.0M$12.0M$-13.0M$64.0M$-143.0M$156.0M
Free Cash Flow$-78.0M$-68.0M$145.0M$21.0M$-280.0M$102.0M$123.0M$274.0M$203.0M$328.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.49
EV / EBITDA2.47
FCF Yield45.71%
Quick Ratio0.84
Interest Coverage0.98
Return 1Y9.81%
Return 3Y57.48%
Return 5Y48.89%

Collegium Pharmaceutical, Inc. (COLL) financials — frequently asked questions

What is Collegium Pharmaceutical, Inc.'s annual revenue?

Collegium Pharmaceutical, Inc. (COLL) reported annual revenue of $781.0M in its most recent fiscal year.

What is Collegium Pharmaceutical, Inc.'s net profit?

Collegium Pharmaceutical, Inc. (COLL) reported net profit of $63.0M in its most recent fiscal year.

What is COLL EV/EBITDA?

Collegium Pharmaceutical, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 2.47.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
COLL Overview COLL Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.